Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Alessandro Cavaliere
Observed names:
A. Cavaliere,
CAVALIERE, ALESSANDRO,
Cavaliere, Alessandro
Institutions:
Candiolo Cancer Institute,
University of Turin
Observed institutions:
University of Verona,
Fudan University Shanghai Cancer Center,
Azienda Ospedaliera Universitaria Integrata Verona,
Candiolo Cancer Institute,
University of Turin
ORCID:
0000-0002-8690-5382
Observed ORCID:
0000-0002-8690-5382
OpenAlex ID:
A5015758395
KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities
2020
·
Claudio Luchini
, Gaetano Paolino
, et al.
·
Journal of Experimental & Clinical Cancer Research
·
107
PDF
Targeting KRAS: The Elephant in the Room of Epithelial Cancers
2021
·
Valeria Merz
, Marina Gaule
, et al.
·
Frontiers in Oncology
·
81
PDF
Pancreatic Cancer and Obesity: Molecular Mechanisms of Cell Transformation and Chemoresistance
2018
·
Priscilla Cascetta
, Alessandro Cavaliere
, et al.
·
International Journal of Molecular Sciences
·
52
PDF
A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal–gastric junction/gastric cancer trastuzumab resistant: the FiGhTeR trial
2020
·
Valeria Merz
, Camilla Zecchetto
, et al.
·
Therapeutic Advances in Medical Oncology
·
44
PDF
Evolving pancreatic cancer treatment: From diagnosis to healthcare management
2021
·
Michele Milella
, Claudio Bassi
, et al.
·
Critical Reviews in Oncology/Hematology
·
38
Organisational challenges, volumes of oncological activity and patients' perception during the severe acute respiratory syndrome coronavirus 2 epidemic
2020
·
Serena Zuliani
, Ilaria Zampiva
, et al.
·
European Journal of Cancer
·
32
PDF
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort
2021
·
U. Peretti
, A. Cavaliere
, et al.
·
ESMO Open
·
31
PDF
Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer
2020
·
Valeria Merz
, Camilla Zecchetto
, et al.
·
Clinical Cancer Research
·
30
Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey
2021
·
G. Orsi
, M. Di Marco
, et al.
·
ESMO Open
·
24
PDF
A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial
2020
·
Francesca Simionato
, Camilla Zecchetto
, et al.
·
Therapeutic Advances in Medical Oncology
·
14
PDF
Novel Biomarkers for Prediction of Response to Preoperative Systemic Therapies in Gastric Cancer
2019
·
Alessandro Cavaliere
, Valeria Merz
, et al.
·
Journal of the Korean Gastric Cancer Association
·
13
PDF
Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients
2020
·
Valeria Merz
, Alessandro Cavaliere
, et al.
·
Cancers
·
12
PDF
DNA demethylation triggers cell free DNA release in colorectal cancer cells
2024
·
Valeria Pessei
, Marco Macagno
, et al.
·
Genome Medicine
·
11
PDF
Role of next-generation genomic sequencing in targeted agents repositioning for pancreaticoduodenal cancer patients
2021
·
Davide Melisi
, Alessandro Cavaliere
, et al.
·
Pancreatology
·
9
Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv)
2022
·
Giulia Orsi
, Alessandro Cavaliere
, et al.
·
British Journal of Cancer
·
8
Real‐World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1 ‐2 Pathogenic Variants
2025
·
Michele Milella
, Giulia Orsi
, et al.
·
Cancer Medicine
·
4
A Comparative Study of Methyl-BEAMing and Droplet Digital PCR for MGMT Gene Promoter Hypermethylation Detection
2024
·
Marco Macagno
, Valeria Pessei
, et al.
·
Diagnostics
·
2
PDF
Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA2 genes
2023
·
Anna Maria Militello
, Giulia Orsi
, et al.
·
Cancer Chemotherapy and Pharmacology
·
2
1701P Oncological patients’ perception of infection risks and level of acceptance of protective measures during SARS-CoV-2 pandemic
2020
·
D. Tregnago
, S. Zuliani
, et al.
·
Annals of Oncology
·
2
PDF
Abstract 6169: Immunogenic cell death mediates the anticancer efficacy of high dose vitamin C
2025
·
Alessandro Cavaliere
, Marco Macagno
, et al.
·
Cancer Research
·
1
Real-world impact of olaparib use in patients (pts) with advanced pancreatic cancer (PC) harboring germline BRCA1/2 (gBRCA) mutations.
2023
·
Michele Milella
, Giulia Orsi
, et al.
·
Journal of Clinical Oncology
·
1
PDF
Calreticulin exposure is a critical mediator of high-dose vitamin C-induced immune surveillance in the tumor microenvironment
2026
·
Alessandro Cavaliere
, Federica Maione
, et al.
·
Molecular Cancer Research
PDF
Abstract 4298: High-dose vitamin C induces ROS-dependent calreticulin exposure to drive immunogenic cell death and cancer immune surveillance
2026
·
Alessandro Cavaliere
, Federica Maione
, et al.
·
Cancer Research
Supplementary TABLE 1 from Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer
2023
·
Valeria Merz
, Camilla Zecchetto
, et al.
Figure S3. from Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer
2023
·
Valeria Merz
, Camilla Zecchetto
, et al.
Show more works
View as search
Works count:
68
Citation count:
518
H-index:
12
I10-index:
13
Year
Topic
Type